Loading...
XNYS
A
Market cap37bUSD
Jul 09, Last price  
133.59USD
1D
3.50%
1Q
16.10%
Jan 2017
193.22%
Name

Agilent Technologies Inc

Chart & Performance

D1W1MN
XNYS:A chart
P/E
28.96
P/S
5.43
EPS
4.61
Div Yield, %
0.56%
Shrs. gr., 5y
-1.86%
Rev. gr., 5y
5.41%
Revenues
6.95b
+6.73%
4,973,000,0005,420,000,0005,774,000,0004,481,000,0005,444,000,0006,615,000,0006,858,000,0003,894,000,0004,048,000,0004,038,000,0004,202,000,0004,472,000,0004,914,000,0005,163,000,0005,339,000,0006,319,000,0006,848,000,0006,833,000,0006,510,000,0006,948,000,000
Net income
1.30b
+1.09%
3,307,000,000638,000,000693,000,000-31,000,000684,000,0001,012,000,0001,153,000,000724,000,000549,000,000401,000,000460,000,000684,000,000316,000,0001,071,000,000719,000,0001,210,000,0001,254,000,0001,240,000,0001,289,000,0001,303,000,000
CFO
1.56b
-10.97%
634,000,000969,000,000756,000,000408,000,000712,000,0001,260,000,0001,228,000,0001,152,000,000713,000,0001,322,000,000793,000,000889,000,0001,087,000,0001,021,000,000921,000,0001,485,000,0001,312,000,0001,772,000,0001,751,000,0001,559,000,000
Dividend
Jan 06, 20260.255 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
IPO date
Nov 18, 1999
Employees
18,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑102025‑042024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT